Phase I studies demonstrated that inhibiting the IGF-1R compensatory responses with mTOR inhibition could yield favorable clinical activity in advanced cancers, particularly in estrogen receptor (ER)-positive/high-proliferative breast carcinoma (Brana et al., 2014). This evidence concerns the gene MTOR and cancer.